RESUMO
UNLABELLED: (32)P has been available for the treatment of myeloproliferative neoplasms (MPNs) for over seventy years. It was first used in 1938 by John H Lawrence in the treatment of polycythaemia and chronic leukaemias. With the introduction of agents such as hydroxycarbamide, interferon and anagrelide the role of (32)P has been diminished. Today, Polycythaemia Rubra Vera (PRV) and Essential Thrombocythaemia (ET) remain the only myeloproliferative conditions in which (32)P is indicated. MATERIALS AND METHODS: We carried out a retrospective review of all patients who had received 32P in Northern Ireland over a 24 year period. The time to successful response, duration of response, and associated complications were reviewed. RESULTS: (32)P was successful in inducing remission in 90% of patients. This remission was sustained following one dose without the need for further therapy in 37% of cases. 47% required repeated doses. 26% required recommencement of alternative therapies. No cases of thrombosis, myelofibrosis or acute leukaemia were observed. DISCUSSION: We conclude that (32)P is a well-tolerated and efficacious treatment option in the elderly. We discuss our results compared with previous work in this area. (32)P will continue to be offered to elderly patients in our practice.
Assuntos
Transtornos Mieloproliferativos , Radioisótopos de Fósforo/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Contagem de Células Sanguíneas/métodos , Feminino , Humanos , Irlanda/epidemiologia , Masculino , Registros Médicos Orientados a Problemas , Transtornos Mieloproliferativos/diagnóstico , Transtornos Mieloproliferativos/epidemiologia , Transtornos Mieloproliferativos/terapia , Avaliação de Processos e Resultados em Cuidados de Saúde , Estudos RetrospectivosRESUMO
PURPOSE: To investigate whether failure to suppress the prostate-specific antigen (PSA) level to Assuntos
Hormônio Liberador de Gonadotropina/agonistas
, Antígeno Prostático Específico/sangue
, Neoplasias da Próstata/sangue
, Neoplasias da Próstata/terapia
, Idoso
, Idoso de 80 Anos ou mais
, Antagonistas de Androgênios/uso terapêutico
, Seguimentos
, Humanos
, Masculino
, Pessoa de Meia-Idade
, Terapia Neoadjuvante/métodos
, Neoplasias da Próstata/mortalidade
, Neoplasias da Próstata/patologia
, Radioterapia Conformacional
, Valores de Referência
, Estudos Retrospectivos
, Taxa de Sobrevida